Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Julia Kollewe

GSK reports promising early results in ovarian and womb cancer drug trial

Infusion pump feeding IV drip into patient's arm
GSK acquired the Mo-Rez treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharm. Photograph: Brian Jackson/Alamy

GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, seeks to speed up drug development at the group.

The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.